The purpose of this legislative text is to enhance the inspection processes for drug manufacturing facilities that produce biosimilar biological products. The goal is to ensure that these inspections are more effective and efficient, ultimately improving the safety and quality of these products for consumers. Key provisions of this legislation include several important actions. First, it mandates a public meeting within 180 days of the law's enactment to discuss how mutual recognition agreements can be used to improve inspections of biosimilar facilities.